| Ginger Lee Davis, SLP | |
|
200 Norfleet Dr, Somerset, KY 42501-1952 | |
| (606) 678-5104 | |
| Not Available |
| Full Name | Ginger Lee Davis |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 200 Norfleet Dr, Somerset, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144428087 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | KY 3010 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ginger Lee Davis, SLP 1180 Ferry Road, Somerset, KY 42503 Ph: (606) 451-9181 | Ginger Lee Davis, SLP 200 Norfleet Dr, Somerset, KY 42501-1952 Ph: (606) 678-5104 |
News Archive
"The U.S. Food and Drug Administration on Monday approved Johnson & Johnson's drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally," the Wall Street Journal reports.
In an age when cohabitation and divorce are common, single parents concerned about the developmental health of their children may want to choose new partners slowly and deliberately, new research from The Johns Hopkins University suggests.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
NPS Pharmaceuticals, Inc. today announced that it intends to offer, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. In connection with this offering, the Company expects to grant to the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock to cover overallotments, if any.
Researchers at the RIKEN Brain Science Institute in Japan have discovered how to reverse the abnormal axonal development characteristic of CFEOM3, a congenital disease that affects the muscles that control eye movements.
› Verified 8 days ago
Mrs. Tamara B Cranfill, CCC/SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 353 Bogle St, Suite 203, Somerset, KY 42503 Phone: 606-679-1761 Fax: 606-678-0971 | |
Allison Kathryn Parrott, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Tower Cir, Somerset, KY 42503 Phone: 606-416-5139 | |
Dr. Sue Ann Losey, ED. D, CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 208 Allen Dr, Somerset, KY 42503 Phone: 606-679-2250 | |
Mackenzie Flynn Epperson, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Tower Cir, Somerset, KY 42503 Phone: 606-416-5139 Fax: 606-416-5239 | |
Alisha Spinks, M.S., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 303 Second St, Somerset, KY 42501 Phone: 606-677-1166 | |
Brittany Gaines, CF-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 303 Second St, Somerset, KY 42501 Phone: 606-677-1166 |